• 한국산학기술학회논문지
• /
• 제12권11호
• /
• pp.5117-5122
• /
• 2011

본 논문에서는 열 해석 시뮬레이션 프로그램인 COMSOL Multiphysics를 활용하여, LED Module의 제작 시, 가장 선호되는 패키지 종류인 COB Type과 보드를 생략한 COH Type의 열 해석 시뮬레이션을 진행한다. LED Module의 시뮬레이션 결과 방열판을 통과하는 위치에 따라 COB Type은 Max. 약 $78^{\circ}C$ ~ Min. 약 $62^{\circ}C$, COH Type은 Max. 약 $88^{\circ}C$ ~ Min. 약 $67^{\circ}C$에서 온도가 안정이 됨을 확인하였다. COB Type과 비교하여 Max. 온도는 약 $10^{\circ}C$ 차이가 나지만, Min. 온도에서 약 $5^{\circ}C$정도로 격차가 감소함을 확인하였으며, LED Point 온도특성곡선을 확인 한 결과 COB Type은 Max. 약 $100^{\circ}C$ ~ Min. 약 $77^{\circ}C$, COH Type은 Max. 약 $100^{\circ}C$ ~ Min. 약 $86^{\circ}C$온도가 안정이 됨을 확인하였으며, COB Type에 비해 COH Type이 약 $10^{\circ}C$ 온도가 높게 측정되었다.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.65-71
• /
• 2003

Terbinafine is a synthetic allylamine that is available in an oral formulation and is used at a dosage of 250mg/day. It is used as an active antifungal agent and inhibits the fungal enzyme squalene epoxidase, which leads to the accumulation of the sterol squalene, which is toxic to the organism. The purpose of the present study was to evaluate the bioequivalence of two terbinafine tablets, Lamisil (Novartis Korea Ltd.) and Terbinex (C-TRI Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 26.00$\pm$2.57 year in age and 70.51$\pm$9.36 kg in body weight, were divided into two groups and a randomized 2${\times}$2 cross-over study was employed. After one tablet containing 125 mg of terbinafine was orally administered, blood was taken at predetermined time intervals and the concentrations of terbinafine in plasma were determined using HPLC with UV detector. Pharmacokinetic parameters such as AUC, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC, $C_{max}$ and $T_{max}$ between two tablets were －4.191％, 5.223％ and －25.720％, respectively when calculated against the Lamisil, tablet. The powers (1-$\beta$) for AUC, $C_{max}$ and $T_{max}$ were 81％, 87％ and below 60％, respectively. Minimum detectable differences(.il) at alpha=O.1 and 1-/3=0.8 were less than 20％ (e.g., 19.72％ and 17.77％ for AUC and $C_{max}$, respectively). But minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 for $T_{max}$ were more than 20％ (e.g., 26.25％). The 90％ confidence intervals were within $\pm$20％ (e.g., －17.440∼9.06 and －6.713∼17.160 for AUC and $C_{max}$ respectively). But 90％ confidence intervals for $T_{max}$ were not within $\pm$20％ (e.g., －43.346∼8.083). Another ANOVA test was conducted for logarithmically transformed AUC and $C_{max}$. These results showed that there are no significant differences in AUC and $C_{max}$ between the two formulations: The differences between the formulations in these log transformed parameters were all for less than 20％ (e.g., －4.19％ and 5.22％ for AUC and $C_{max}$, respectively). The 90％ confidence intervals for the log transformed data were not the acceptance range of log 0.8 to log 1.25 in AUC but the acceptance range of log 0.8 to log 1.25 in $C_{max}$ (e.g., log 1.13∼log 1.50 and log 0.94-log 1.22 for AUC and $C_{max}$ respectively). The major parameters, AUC and $C_{max}$ met the criteria of KFDA for bioequivalence although $T_{max}$ did not meet the criteria of KFDA (1998 year) for bioequivalence, indicating that Onfran tablet is bioequivalent to Zofran tablet. But in another ANOVA test AUC did not meet the criteria of KFDA (2002) for bioequivalence but $C_{max}$ met the criteria of KFDA (2002 year) for bioequivalence.or bioequivalence.equivalence.equivalence.equivalence.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.58-64
• /
• 2003

Ondansetron is a potent, highly selective 5-hydroxytryptamin $e_3$(5-H $T_3$) receptor-antagonist, for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiography, and the treatment of post-operative nausea and vomiting. The purpose of the present study was to evaluate the bioequivalence of two ondansetron tablets, Zofran (Glaxo Smithcline Korea Ltd.) and Onfran (Korea United Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 24.39$\pm$1.69 year in age and 69.00$\pm$6.74kg in body weight, were divided into two groups and a randomized 2${\times}$2 cross-over study was employed. After one tablet containing 8mg of ondansetron was orally administered, blood was taken at predetermined time intervals and the concentrations of ondansetron in plasma were determined using HPLC with UV detector. Pharmacokinetic parameters such as AVC, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC, $C_{max}$ and T max between two tablets were 5.83％, 5.75％ and －5.71％, respectively when calculated against the Zofran, tablet. The powers (1-$\beta$) for AUC, $C_{max}$ and $T_{max}$ were above 90％, above 90％ and below 60％, respectively. Minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 were less than 20％ (e.g., 12.74％ and 11.78％ for AUC and $C_{max}$ respectively). But minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 for $T_{max}$ were more than 20％ (e.g., 34.22％). The 90％ confidence intervals were within $\pm$20％ (e.g., -2.73∼14.39 and -2.16∼13.67 for AUC and $C_{max}$ respectively). But 90％ confidence intervals for $T_{max}$ were not within $\pm$20％ (e.g., -28.71∼17.28). Another ANOVA test was conducted for logarithmically transformed AUC and $C_{max}$. These results showed that there are no significant difference in AUC and $C_{max}$ between the two formulations: The differences between the formulations in these log transformed parameters were all for less than 20％ (e.g., 5.83％ and 5.75％ for AUC and $C_{max}$ respectively). The 90％ confidence intervals for the log transformed data were the acceptance range of log 0.8 to log 1.25 (e.g., log 0.99∼log 1.15 and log 0.98∼log 1.15 for AUC and $C_{max}$ respectively). The major parameters, AUC and $C_{max}$, met the criteria of KFDA for bioequivalence although $T_{max}$ did not meet the criteria of KFDA for bioequivalence, indicating that Onfran tablet is bioequivalent to Zofrm1 tablet.t is bioequivalent to Zofrm1 tablet.m1 tablet.m1 tablet.m1 tablet.

• Biomolecules & Therapeutics
• /
• 제9권4호
• /
• pp.285-290
• /
• 2001

Bioequivalence of two acetyl-1-carnitine tablets, test product (Carnitile tablet: Hanmi Pharm. Co., Ltd.) and reference product (Nicetil $e^{R}$ tablet: Dong-A Pharm. Co., Ltd.), was evaluated according to the guide- lines of Korea Food and Drug Administration (KFDA). Twenty-six healthy volunteers were divided randomly into two groups and administered the drug orally at the dose of 500 mg as acetyl-1-carnitine in a 2$\times$2 crossover study. Blood samples were taken at predetermined time intervals for 12 hours and the plasma concentration of acetyl-1-carnitine was determined using HPLC by derivatization with p-bromophenacyl bromide. The pearmacokinetic parameters (AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$) were calculated and ANOVA was utilized for the statistical analysis of parameters. The apparent differences of these parameters between two drugs were less than 20% (i.e., 1.26,-5.08 and 8.59% for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, respectively). The powers (1-$\beta$) for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, and Tmax were over 0.9. Minimal detectable difference ($\Delta$) at $\alpha$=0.05, 1-$\beta$=0.8 were less than 20% (i.e.,7.31, 14.88 and 11.77% for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, respectively). The confidence intervals ($\delta$) for these parameters were also within $\pm$ 20% (i.e.,-3.03$\leq$$\delta$$\leq$5.54, -13.80$\leq$$\delta$$\leq$3.64 and 1.69$\leq$$\delta$$\leq$15.48 for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, respectively). These results satisfied the criteria of KFDA guideline for bioequivalence, indicating Carnitile bioequivalent to Nicetil $e^{R}$ .TEX>$^{R}$ .> R/ . R/ .

• 생명과학회지
• /
• 제13권1호
• /
• pp.59-66
• /
• 2003

Starter로 사용하기 위하여 $20^{\circ}C$에서 4일간 발효된 돌산 갓김치에서 미생물을 분리하였다. 이를 starter로 접종하여 $4^{\circ}C$와 $10^{\circ}C$에서 50일간 발효시키면서 발효특성, 항산화활성, ACE 저해활성을 조사하였다. 1 X $10^{10}$ CFU/mL의 접종농도에서 적숙기(pH 4.5)에 도달하는 시간이 $4^{\circ}C$에서는 최고 5.6배 이상, $10^{\circ}C$에서는 5배 단축되었다. 총균수는 starter 접종농도가 높을수록 발효초부터 높은 균수를 유지하였다. 항산화활성도 starter 접종농도가 높을수록 전반적으로 골게 나타났고, 1 X $10^{10}$ CFU/mL의 접종농도에서 $4^{\circ}C$와 $10^{\circ}C$ 각각 최대 67%와 75%를 나타내었다. 따라서 단위 시간당 세포의 생성율($lnX_{max}$/$t_{max}$)과 항산화활성($lnX_{max}$/$t_{max}$)은 비례관계를 가지며, 초기 접종농도가 높을수록 단위 시간 당 항산화활성이 높음을 알 수 있었다. ACE 저해활성도starter의 농도가 높을수록 ACE 저해활성도 놀게 나타났다. 즉, 1 X $10^{10}$ CFU/mL의 접종농도에서 $4^{\circ}C$에서는 52%, $10^{\circ}C$에서는 최대 76%를 나타내었다. 파라서 일정시간당 체포의 생성율($lnX_{max}$/$t_{max}$)이 증가할수록 ACE 저해율 ($P_{max}$/$t_{max}$)도 증가하였으며, 초기 접종농도가 높을수록 단 위 시간당 ACE 저해율이 높았다.

• 한국전기전자재료학회논문지
• /
• 제33권6호
• /
• pp.515-520
• /
• 2020

The Ti₃SiC₂ MAX phase was synthesized by arc-melting process under three different processing times. We confirmed that the reaction between the TiC_X phase and Ti-Si liquid phase is important for the synthesis of the Ti₃SiC₂ MAX phase. Results suggest that the Ti₃SiC₂ MAX phase decomposed when the arc-melting time was greater than 80s. Herein, we aim to determine the detailed parameters for the reported arc-melting process, which can provide useful insights on the synthesis of the Ti₃SiC₂ MAX phase by arc-melting process. Furthermore, we compared the electrical characteristics and densities of the three samples.

• 한국안광학회지
• /
• 제5권1호
• /
• pp.43-48
• /
• 2000

Polarizer와 Analyzer의 Rotation 각에 의해 광의 luminance를 조절할 수 있다. Contrast Sensitivity에 대응한 luminance 값 $L_{max}$, $L_{min}$은 평균 luminance($L_m$)의 회전각 ${\theta}_m$ 최대 진폭과 최소 진폭에 대응하는 회전각 (${\theta}_{max}$, ${\theta}_{min}$)로 부터 구할 수 있다. $$L_{max}=I(0)e^{-2at}{\cdot}cos^2{\theta}_m(1+C_s^{-1})$$ $$L_{min}=I(0)e^{-2at}{\cdot}cos^2{\theta}_m(1-C_s^{-1})$$ 평균 luminance($L_m$)의 회전각 ${\theta}_m$과 측정할 Contrast Sensitivity($C_s$)로부터 polarizer와 analyzer의 회전각(${\theta}_{max}$, ${\theta}_{min}$)을 얻었다. $${\theta}_{max}=cos^{-1}[cos{\theta}_m{\cdot}(1+C_s^{-1})^{1/2}]$$ $${\theta}_{min}=cos^{-1}[cos{\theta}_m{\cdot}(1-C_s^{-1})^{1/2}]$$.

• Journal of Pharmaceutical Investigation
• /
• 제24권2호
• /
• pp.49-55
• /
• 1994

Bioequivalence test of commercially available rifampicin capsules was performed. Sixteen volunteers were divided into 2 groups and the reference and test drug were given orally (450 mg) by cross-over design. Statistical evaluation of AUC, $C_{max}\;and\;T_{max}$ involved an analysis of variance (ANOVA). The differences of mean value in AUC, $C_{max}\;and\;T_{max}$ between the reference and test drug were within 20% with reference drug. ANOVA showed no significant differences for ‘between group’, ‘drug’ and ‘period’, but not for ‘between subjects’. The power of test $(1-{\beta})\;of\;AUC\;and\;$C_{max}$ was larger than 0.8 and the confidence of bioavailability was $within\;{\pm}20%$. From these results, it was concluded that the two preparations were bioequivalent for AUC and $C_{max}$, but was not for $T_{max}$.

• 한국지반공학회:학술대회논문집
• /
• 한국지반공학회 2009년도 춘계 학술발표회
• /
• pp.331-340
• /
• 2009

This study evaluates the relationship between cone tip resistance ($q_c$) and small-strain shear modulus ($G_{max}$) of cemented sand. For this purpose, a series of miniature cone penetration and bender element tests are performed in calibration chamber specimens with various gypsum contents. Experimental results show that both $q_c$ and $G_{max}$ of sand increase with increasing cementation level as well as relative density and vertical confining stress. However, the relative density and vertical confining stress has more significant influence on $G_{max}$ and $q_c$ of uncemented sand than those of cemented sand. It is observed that the $G_{max}/q_c$ ratio of cemented sand decreases with increasing relative density. This result means that state variables have more affect on $q_c$ than $G_{max}$ of cemented sand. Test results also show that the effect of vertical stress on $G_{max}-q_c$ relation is reduced by cementation effect.

• Biomolecules & Therapeutics
• /
• 제7권1호
• /
• pp.59-65
• /
• 1999

A bioequivalence study of the Dong Wha Cisapril tablets(Dong Wha Pharm. Ind. Co., Ltd.) to the Prepulsid tablets(Janssen Korea Ltd.), formulations of cisapride, was conducted. Twenty four healthy Korean male subjects received each formulation at the dose of 5 mg as cisapride in a 2$\times$2 crossover study. There was a 1-week washout period between the doses. Plasma concentrations of cisapride were monitored by an LC/MS method for over a period of 36 h after each administration. AUC(area under the plasma concentration- time curve from time zero to infinity) was calculated by the linear trapezoidal and extrapolation method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) revealed that there are no differences in AUC, $C_{max}$ and $T_{max}$ between the formulations. The apparent differences between the formulations in these parameters were all far less than 20% (i.e., 6.8, -6.6 and 1.8% for AUC, $C_{max}$ and $T_{max}$, respectively). Minimum detectable differences(%) at $\alpha$=0.05 and 1-$\beta$=0.8 were all less than 20% in these parameters between the formulations (i.e., 16.5, 11.4 and 16.4% for AUC, $C_{max}$ and $T_{max}$, respectively). The 90% confidence intervals for these parameters were also within 20% (i.e., -2.9~ 16.4, -13.2~0.1 and -7.8~ 11.4% for AUC, $C_{max}$ and $T_{max}$, respectively). These results satisfy the bioequivalence criteria of the Korea Food and Drug Administration (KFDA) guidelines (No. 98-51). Therefore, these results indicate that the two formulations of cisapride are bioequivalent and, thus, may be prescribed interchangeably.hangeably.y.hangeably.